Schedule 14D-9 being mailed to SCTL shareholders with this Offer to Purchase. Other than as described below, there have been no material contacts between SCTL and Parent in the past two years.
On October 25, 2023, while attending the Convention on Pharmaceutical Ingredients (CPhI) annual European conference in Barcelona, Spain, representatives of Raymond James introduced David Enloe, SCTL’s Chief Executive Officer, to Ashton Poole, a partner at QHP Capital, L.P. (“QHP Capital”), and Jeffrey Edwards, a partner at QHP Capital and a current board member of Parent. During this initial meeting, the parties discussed the CDMO market landscape.
Following this initial interaction, on October 27, 2023, QHP Capital entered into a confidentiality agreement with SCTL, which agreement contained a standstill obligation.
On November 17, 2023, Mr. Edwards and other representatives of Parent met with Mr. Enloe, Ryan Lake, SCTL’s Chief Financial Officer, Scott Rizzo, SCTL’s Chief Operating Officer, and Richard Sidwell, Ph.D., SCTL’s Chief Strategy Officer, in Atlanta, Georgia. During this meeting, the parties discussed, among other topics, whether there was a strategic and cultural fit between Parent and SCTL. However, the financial terms of a potential transaction were not discussed during this meeting.
On November 20, 2023, representatives of Parent requested certain preliminary due diligence materials from SCTL to better inform its view on a potential transaction with SCTL.
On December 12, 2023, Parent received a process letter regarding a potential sale of SCTL’s 24,500 square foot development facility located in San Diego, California (the “San Diego Site”).
On December 17, 2023, representatives of Parent visited the San Diego Site and met with Mr. Enloe, Erica Raether, SCTL’s chief people officer, and Tim Bourque, SCTL’s Vice President of Operations & Site Head.
Following the San Diego Site visit, on December 27, 2023, at the request of representatives of Parent, representatives of Parent and certain members of the SCTL Board met virtually to discuss Parent’s potential interest in a transaction with SCTL and to provide information concerning the investment strategy and thesis of QHP Capital and its portfolio companies, including Parent. Representatives of Raymond James were also present at the meeting. No financial or transaction terms were discussed at this meeting.
On January 2, 2024, based on diligence conducted to date, Parent submitted a non-binding indication of interest to acquire SCTL at a price range of $1.00 – $1.20 per Share, assuming that existing SCTL shareholders representing 25–45% of the outstanding Shares reinvest their Shares in Parent pursuant to a “rollover” transaction (the “Initial Proposal”). The Initial Proposal was subject to SCTL entering into an exclusivity agreement requiring SCTL to negotiate exclusively with Parent for a period of not less than 45 days. The closing price per Share of SCTL common stock on Nasdaq on that day was $0.41.
On January 5, 2024, at the direction of the SCTL Board, representatives of Raymond James communicated to representatives of Parent that the SCTL Board was not prepared to enter exclusivity at that time but encouraged Parent to continue evaluating the proposed transaction in order to put forth a revised proposal. Representatives of Raymond James also communicated, at the direction of the SCTL Board, that any transaction requiring a substantial rollover presented significant complexities for the SCTL Board and that further extensive detail about Parent’s operations and financials would be needed to support entering into exclusivity for a transaction requiring a substantial rollover component. Representatives of Parent communicated to representatives of Raymond James that Parent was also considering alternative acquisition targets and would require an exclusivity commitment in order to continue pursuing a potential transaction with SCTL.
On January 7, 2024, Mr. Edwards, Mr. Poole and other representatives from Parent met with Mr. Enloe in San Francisco, California to discuss potential growth opportunities related to a combined company.
24